A detailed history of Main Street Group, LTD transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Main Street Group, LTD holds 200 shares of CHRS stock, worth $208. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200
Previous 200 -0.0%
Holding current value
$208
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$2.02 - $3.14 $404 - $628
200 New
200 $0
Q4 2023

Feb 15, 2024

BUY
$1.59 - $3.85 $0 - $0
0 New
0 $0

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $80.8M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Main Street Group, LTD Portfolio

Follow Main Street Group, LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Main Street Group, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Main Street Group, LTD with notifications on news.